| 2024-09-14 |
[Corrections] Correction to Lancet Diabetes Endocrinol 2024; 12: 39–50 |
|
|
| 2024-09-13 |
[Editorial] The unhealthy politics of health |
The Lancet Diabetes & Endocrinology |
|
| 2024-09-10 |
[Comment] Muscle matters: the effects of medically induced weight loss on skeletal muscle |
Carla M Prado, Stuart M Phillips, M Cristina Gonzalez, Steven B Heymsfield |
|
| 2024-09-07 |
[Articles] Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial |
Mikhail N Kosiborod, Sheryl L Windsor, Orly Vardeny, Jeffrey S Berger, Harmony R Reynolds, Stavroula Boumakis, Andrew D Althouse, Scott D Solomon, Ankeet S Bhatt, Alexander Peikert, James F Luther, Eric S Leifer, Andrei L Kindzelski, Mary Cushman, Michell |
|
| 2024-09-07 |
[Articles] Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials |
Claire Vale, Peter J Godolphin, David Fisher, Peter W Horby, Mikhail N Kosiborod, Judith S Hochman, Katie Webster, Julian P T Higgins, Andrew D Althouse, Otavio Berwanger, Remo H M Furtado, Samvel B Gasparyan, Richard Haynes, Gary G Koch, Martin Landray, |
|
| 2024-09-07 |
[Comment] Sodium–glucose co-transporter type-2 inhibitors for hospitalised patients with COVID-19: safe but not protective |
André J Scheen |
|
| 2024-09-07 |
[Articles] Islet-after-kidney transplantation versus kidney alone in kidney transplant recipients with type 1 diabetes (KAIAK): a population-based target trial emulation in France |
Mehdi Maanaoui, Rémi Lenain, Yohann Foucher, Fanny Buron, Gilles Blancho, Corinne Antoine, Sophie Caillard, Laurence Kessler, Moglie Le Quintrec, Orianne Villard, Dany Anglicheau, Matthias Büchler, Albane Brodin-Sartorius, Luc Frimat, Paolo Malvezzi, Sand |
|
| 2024-09-07 |
[Comment] Islet transplantation in kidney transplant recipients with type 1 diabetes |
Shareen Forbes, Thomas W H Kay |
|
| 2024-09-05 |
[Comment] International Day of Charity: what does charity mean for diabetes? |
David Beran, Stéphane Besançon |
|
| 2024-09-04 |
[In Focus] Reducing sodium intake: step-by-step targets yield success |
Talha Burki |
|
| 2024-09-04 |
[Corrections] Correction to Lancet Diabetes Endocrinol 2024; 12: 602–03 |
|
|
| 2024-08-30 |
[Articles] Adiposity and metabolic health in Asian populations: an epidemiological study using dual-energy x-ray absorptiometry in Singapore |
Theresia Mina, Wubin Xie, Dorrain Yanwen Low, Xiaoyan Wang, Benjamin Chih Chiang Lam, Nilanjana Sadhu, Hong Kiat Ng, Nur-Azizah Aziz, Terry Yoke Yin Tong, Swat Kim Kerk, Wee Lin Choo, Guo Liang Low, Halimah Ibrahim, Liming Lim, E Shyong Tai, Gervais Wansa |
|
| 2024-08-30 |
[Comment] Why does visceral adiposity not explain higher type 2 diabetes prevalence in Asian Indians? |
Viswanathan Mohan, Ranjit Mohan Anjana |
|
| 2024-08-27 |
[Comment] Transitioning to stage 3 type 1 diabetes: when to start insulin |
Rachel E J Besser, Kurt J Griffin |
|
| 2024-08-22 |
[Correspondence] Sociodemographic and health-related differences in non-diabetic hyperglycaemia and undiagnosed type 2 diabetes in England during 2013–19: a cross-sectional study |
Emma Campbell, Ellie Macey, Caitlin Kneebone-Hopkins, Chris Shine, Vahé Nafilyan, Nicholas Brown, Martin White, Ross Jones, Kamlesh Khunti, Katie Finning |
|
| 2024-08-21 |
[Correspondence] Association of age with gaps in diabetes-related care and hospitalisations from childhood to young adulthood in Quebec, Canada: a cohort study |
Meranda Nakhla, Elham Rahme, Marc Simard, Véronique Boiteau, Kaberi Dasgupta |
|
| 2024-08-21 |
[Comment] Paediatric thyroid lesions: lessons from recent guidelines |
Esther Diana Rossi, Huiying Wang, Vivian Lee Weiss |
|
| 2024-08-21 |
[Comment] Closed-loop systems: a bridge to cell therapy for type 1 diabetes? |
Sufyan Hussain, Katarina Braune, Shareen Forbes, Peter A Senior |
|
| 2024-08-17 |
[Comment] Increased prevalence of younger onset type 2 diabetes: why and what could be done? |
Naveed Sattar, Brian Kennon, Anna D White |
|
| 2024-08-17 |
[Review] Male hypogonadism: pathogenesis, diagnosis, and management |
Nipun Lakshitha De Silva, Nikoleta Papanikolaou, Mathis Grossmann, Leen Antonio, Richard Quinton, Bradley David Anawalt, Channa N Jayasena |
|
| 2024-08-09 |
[Editorial] Diabetes-related complications: a toll too high |
The Lancet Diabetes & Endocrinology |
|
| 2024-08-07 |
[Comment] Implementing type 2 diabetes remission interventions in the real world: what have we learnt? |
Srikanth Bellary |
|
| 2024-08-06 |
[Articles] Early findings from the NHS Type 2 Diabetes Path to Remission Programme: a prospective evaluation of real-world implementation |
Jonathan Valabhji, Tessa Gorton, Emma Barron, Soraya Safazadeh, Fiona Earnshaw, Clare Helm, Martin Virr, John Kernan, Shaun Crowe, Paul Aveyard, John Wilding, Tony Willis, Louisa Ells, Simon O'Neill, Elizabeth Robertson, Susan Jebb, Roy Taylor, Chirag Bak |
|
| 2024-08-02 |
[Personal View] Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes |
Muhammad Abdul-Ghani, Pietro Maffei, Ralph Anthony DeFronzo |
|
| 2024-08-02 |
[Comment] Sex differences in familial hypercholesterolaemia |
Xavier Rossello, Francisca Caimari |
|
| 2024-08-02 |
[Corrections] Correction to Lancet Diabetes Endocrinol 2024; published online July 19. https://doi.org/10.1016/S2213-8587(24)00157-8 |
|
|
| 2024-08-02 |
[Articles] Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicentre, prospective cohort study |
Leopoldo Pérez de Isla, Antonio J Vallejo-Vaz, Gerald F Watts, Ovidio Muñiz-Grijalvo, Rodrigo Alonso, Jose L Diaz-Diaz, Raquel Arroyo-Olivares, Rocio Aguado, Rosa Argueso, Marta Mauri, Manuel J Romero, Pilar Álvarez-Baños, Dolores Mañas, José María Cepeda |
|
| 2024-08-02 |
[In Focus] Iodine deficiency in Europe: vigilance and action required |
Talha Burki |
|
| 2024-07-30 |
[Articles] Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial |
Barbara M McGowan, Jens M Bruun, Matt Capehorn, Sue D Pedersen, Kirsi H Pietiläinen, Hanna Angelene Kudiyanur Muniraju, Maria Quiroga, Anette Varbo, David C W Lau, STEP 10 Study Group |
|
| 2024-07-30 |
[Comment] Prediabetes remission in people with obesity |
Michael Bergman |
|
| 2024-07-26 |
[Correspondence] Embracing community sport to promote global health |
Nikolaj Gilbert, Oliver Dudfield, Fiona Bull |
|
| 2024-07-25 |
[Corrections] Correction to Lancet Diabetes Endocrinol 2024; published online July 22. https://doi.org/10.1016/S2213-8587(24)00163-3 |
|
|
| 2024-07-23 |
[Review] Bone health in adults with obesity before and after interventions to promote weight loss |
Julien Paccou, Juliet E Compston |
|
| 2024-07-20 |
[Review] Understanding the cause of type 2 diabetes |
Roy Taylor |
|
| 2024-07-16 |
[Correspondence] The evidence for achondroplasia in 1st century AD Italy |
Francesco M Galassi, Laura Landini, Kristina Killgrove, Marco Artico, Lorenzo Rossi, Veronica Papa, Elena Varotto |
|
| 2024-07-12 |
[Editorial] Precision nutrition: a step too far? |
The Lancet Diabetes & Endocrinology |
|
| 2024-07-10 |
[In Focus] The deep pockets of health-harming industries |
Talha Burki |
|
| 2024-07-09 |
[Comment] SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination? |
Carlos Escobar Cervantes |
|
| 2024-07-09 |
[Articles] Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials |
Ellen M Apperloo, Brendon L Neuen, Robert A Fletcher, Niels Jongs, Stefan D Anker, Deepak L Bhatt, Javed Butler, David Z I Cherney, William G Herrington, Silvio E Inzucchi, Meg J Jardine, Chih-Chin Liu, Kenneth W Mahaffey, Darren K McGuire, John J V McMur |
|
| 2024-07-03 |
[Correspondence] Impact of higher BMI on cardiometabolic risk: does height matter? |
Norbert Stefan, Catarina Schiborn, Jürgen Machann, Andreas L Birkenfeld, Matthias B Schulze |
|
| 2024-07-02 |
[Articles] Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial |
Allison Ross Eckard, Qian Wu, Abdus Sattar, Kianoush Ansari-Gilani, Danielle Labbato, Theresa Foster, Aaron A Fletcher, Ruth O Adekunle, Grace A McComsey |
|
| 2024-07-02 |
[Comment] Semaglutide in people with HIV-associated lipohypertrophy |
Y Joseph Hwang, Todd T Brown, Jacqueline Capeau |
|
| 2024-06-26 |
[Viewpoint] The potential role for artificial intelligence in fracture risk prediction |
Namki Hong, Danielle E Whittier, Claus-C Glüer, William D Leslie |
|
| 2024-06-24 |
[Articles] Early pregnancy HbA1c as the first screening test for gestational diabetes: results from three prospective cohorts |
Ponnusamy Saravanan, Mohan Deepa, Zain Ahmed, Uma Ram, Tarakeswari Surapaneni, Sailaja Devi Kallur, Papa Desari, Seshadri Suresh, Ranjit Mohan Anjana, Wesley Hannah, Chockalingam Shivashri, Saite Hemavathy, Nithya Sukumar, Wycliffe K Kosgei, Astrid Christ |
|
| 2024-06-24 |
[Comment] Value of early pregnancy HbA1c to predict gestational diabetes |
Yashdeep Gupta, David Simmons |
|
| 2024-06-18 |
[Comment] Call for effective therapies for preventing dementia in people with type 2 diabetes |
Thomas T van Sloten, José A Luchsinger, Lenore J Launer, Mark Strachan, Tali Cukierman-Yaffe, Hertzel C Gerstein, Naveed Sattar, Geert Jan Biessels |
|
| 2024-06-07 |
[Editorial] Alarming rise in young-onset type 2 diabetes |
The Lancet Diabetes & Endocrinology |
|
| 2024-06-04 |
[Articles] Associations between BMI and hospital resource use in patients hospitalised for COVID-19 in England: a community-based cohort study |
James Altunkaya, Carmen Piernas, Koen B Pouwels, Susan A Jebb, Philip Clarke, Nerys M Astbury, Jose Leal |
|
| 2024-06-04 |
[Comment] Association between BMI and COVID-19 on hospital budgets |
Maya Nitecki, Arnon Afek, Gilad Twig |
|
| 2024-05-31 |
[Review] Causes, prevention, and management of diabetes-related foot ulcers |
William Jeffcoate, Edward J Boyko, Fran Game, Prue Cowled, Eric Senneville, Robert Fitridge |
|
| 2024-05-31 |
[Comment] Diabetes distress: the psychological burden of living with diabetes |
Lydia Poole, Ruth A Hackett |
|
| 2024-05-31 |
[Correspondence] Lack of access to insulin: undermining the Rights of the Child |
Olivia Heller, Olivier Duperrex, Philip D Jaffé, Jeffrey Goldhagen, Carol A Abidha, Ann Skelton, Mikiko Otani, Yvon Heller, Jean-Dominique Vassalli, David Beran |
|
| 2024-05-28 |
[Personal View] Advancing diabetes surveillance ecosystems: a case study of India |
Jithin Sam Varghese, Emily N Peterson, Mohammed K Ali, Nikhil Tandon |
|
| 2024-05-24 |
[Personal View] Prediction of progression to type 1 diabetes with dynamic biomarkers and risk scores |
Mugdha V Joglekar, Simranjeet Kaur, Flemming Pociot, Anandwardhan A Hardikar |
|
| 2024-05-23 |
[Comment] Measuring serum testosterone in women |
David J Handelsman, Susan R Davis |
|
| 2024-05-21 |
[In Focus] The ongoing quest for worldwide iodine sufficiency |
Ray Cavanaugh |
|
| 2024-05-18 |
[Articles] Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis |
Muhammad Shariq Usman, Deepak L Bhatt, Ishaque Hameed, Stefan D Anker, Alice Y Y Cheng, Adrian F Hernandez, William Schuyler Jones, Muhammad Shahzeb Khan, Mark C Petrie, Jacob A Udell, Tim Friede, Javed Butler |
|
| 2024-05-18 |
[Comment] SGLT2 inhibitors in clinical practice |
Lars Rydén, Anna Norhammar |
|
| 2024-05-11 |
[Editorial] Sleep: a neglected public health issue |
The Lancet Diabetes & Endocrinology |
|
| 2024-05-07 |
[Review] Sex, race, and BMI in clinical trials of medications for obesity over the past three decades: a systematic review |
Moath S Alsaqaaby, Sarah Cooney, Carel W le Roux, Dimitri J Pournaras |
|
| 2024-05-07 |
[Correspondence] Effect of population-wide screening for presymptomatic early-stage type 1 diabetes on paediatric clinical care |
Ezio Bonifacio, Christiane Winkler, Peter Achenbach, Anette-Gabriele Ziegler |
|
| 2024-05-07 |
[Corrections] Correction to Lancet Diabetes Endocrinol 2024; 12: 233–46 |
|
|
| 2024-05-07 |
[Corrections] Correction to Lancet Diabetes Endocrinol 2024; 12: 301–02 |
|
|
| 2024-05-04 |
[Articles] Use of melatonin supplements and risk of type 2 diabetes and cardiovascular diseases in the USA: insights from three prospective cohort studies |
Yanping Li, Tianyi Huang, Susan Redline, Walter C Willett, JoAnn E Manson, Eva S Schernhammer, Frank B Hu |
|
| 2024-05-04 |
[Comment] Melatonin: is it really a cardiovascular wonder pill for shift workers? |
Pei Xue, Diana A Nôga, Christian Benedict |
|
| 2024-04-30 |
[Articles] Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial |
Christian L Roth, Cecilia Scimia, Ashley H Shoemaker, Michael Gottschalk, Jennifer Miller, Guojun Yuan, Sonali Malhotra, M Jennifer Abuzzahab |
|
| 2024-04-30 |
[Articles] Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial |
Katrien Benhalima, Kaat Beunen, Nancy Van Wilder, Dominique Ballaux, Gerd Vanhaverbeke, Youri Taes, Xavier-Philippe Aers, Frank Nobels, Joke Marlier, Dahae Lee, Joke Cuypers, Vanessa Preumont, Sarah E Siegelaar, Rebecca C Painter, Annouschka Laenen, Piete |
|
| 2024-04-30 |
[Comment] Demarcating the benefits of hybrid closed loop therapy in pregnant women with type 1 diabetes |
Helen R Murphy, Eleanor M Scott |
|
| 2024-04-30 |
[Comment] Setmelanotide: new promise for the treatment of hypothalamic obesity? |
Manuel Tena-Sempere |
|
| 2024-04-25 |
[Comment] Bone mineral density as a surrogate endpoint for fracture risk reduction in clinical trials of osteoporosis therapies: an update on SABRE |
Dennis M Black, Austin R Thompson, Richard Eastell, Mary L Bouxsein |
|
| 2024-04-20 |
[Editorial] Earth Day: time for transformational change |
The Lancet Diabetes & Endocrinology |
|
| 2024-04-18 |
[Correspondence] Improving support for university students with type 1 diabetes |
Gijsbert Stoet, Emily Foster, Catherine Kerr, Lingqing Jiang, Megan-Ann Thornhill, Katarzyna Cyranka, Bartłomiej Matejko, Dominika Sarna-Palacz, Magdalena Płonka-Stępień, Tomasz Klupa |
|
| 2024-04-09 |
[Review] Endocrine health in survivors of adult-onset cancer |
Cornelia S Link-Rachner, Andy Göbel, Nikolai P Jaschke, Tilman D Rachner |
|
| 2024-04-06 |
[Articles] Associations of the glycaemic index and the glycaemic load with risk of type 2 diabetes in 127 594 people from 20 countries (PURE): a prospective cohort study |
Victoria Miller, David A Jenkins, Mahshid Dehghan, Kristie Srichaikul, Sumathy Rangarajan, Andrew Mente, Viswanathan Mohan, Sumathi Swaminathan, Rosnah Ismail, Maria Luz Diaz, Rekha M Ravindran, Katarzyna Zatonska, Ahmad Bahonar, Yuksel Altuntas, Rasha Kh |
|
| 2024-04-06 |
[Comment] Glycaemic index as part of the diabetes prevention strategy |
Gary Frost |
|
| 2024-04-06 |
[In Focus] Direct-to-consumer services: improving access to care for people with diabetes and obesity |
Talha Burki |
|
| 2024-03-30 |
[Articles] Familial aggregation and heritability of childhood-onset and adult-onset type 1 diabetes: a Swedish register-based cohort study |
Yuxia Wei, Shengxin Liu, Tomas Andersson, Maria Feychting, Ralf Kuja-Halkola, Sofia Carlsson |
|
| 2024-03-30 |
[Comment] Type 1 diabetes: heterogeneity in heritability |
Richard David Leslie |
|
| 2024-03-28 |
[Articles] Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis |
Cholesterol Treatment Trialists’ (CTT) Collaboration |
|
| 2024-03-28 |
[Comment] How clinically relevant is statin-induced diabetes? |
Hertzel C Gerstein, Marie Pigeyre |
|
